Non-opioid Pain Patches Market Outlook – 2022-2029

Sales in the global Non-Opioid Pain Patches Market are slated to top US$ 3.3 Bn in 2022. Expanding at a healthy 4.1% CAGR, the market size is projected to total US$ 4.4 Bn by 2029.

Attribute Details
Non-opioid Pain Patches Market Estimated Size 2022 US$ 3.3 Billion
Non-opioid Pain Patches Market Value-based CAGR (2022-2029) ~ 4.1%
Non-opioid Pain Patches Market Size in Projected 2029 US$ 4.4 Billion

The deeper impact of pain on the socio-economic system than the combination of diabetes, cancer, and cardiovascular diseases together is likely to drive the sales in this market. The rising cases of chronic pain stoked by back strain due to heavy lifting, accident, or underlying diseases, such as arthritis, spine disease, and pancreatitis are projected to propel the demand for non-narcotic pain patches.

The increasing preference for non-opioid pain relief patches owing to their ability to prevent the risk of addiction, as compared to fentanyl patches when released over a long period of time, is another vital factor that is anticipated to drive the market. The surging demand for minimally invasive treatments is expected to affect the growth positively in the near future.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars Details
H1, 2021 3.64%
H1, 2022 Projected 4.09%
H1, 2022 Outlook 3.29%
BPS Change - H1, 2022 (O) - H1, 2022 (P) (-) 20 ↓
BPS Change - H1, 2022 (O) - H1, 2021 (+) 25 ↑

The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 20 BPS units. However, a positive BPS growth in H1-2022 over H1-2021 by 25 Basis Point Share (BPS) is demonstrated by the market. The non-opioid pain patches market is highly subject to regulatory considerations, licensing of products, and patented approvals of non-opioid pain therapies.

The use of opioids for non-malignant chronic pain in limited situations due to the opioid epidemic that is presently raging in the United States, according to the most recent Centers for Disease Control (CDC) guidelines, is a prime factor resulting in a major decline in the BPS values.

Conversely, the presence of pain relieving products such as prescription and over-the-counter aspirin, ibuprofen, and acetaminophen, and nondrug remedies, have contributed to the positive BPS outlook. The key developments in the market include the development of bio-compatible surgical patches which release the non-opioid painkillers directly to the site of the wound.

2014-2021 Non-opioid Pain Patches Market Outlook in Comparison to 2022-2029 Growth Forecast

The non-opioid pain patches market is expected to register 4.1% CAGR between 2022 and 2029, up from 2.6% CAGR recorded during 2014-2021, predicts Future Market Insights.

The ability of non-opioid heat therapy patches to release Active Pharmaceutical Ingredients (APIs) for delivering therapeutic effects by blocking the body’s sensation of pain signals through receptors is set to accelerate the market in the evaluation period. The urgent need to ease muscle spasms and reduce discomfort in patients suffering from muscular or joint disorders is likely to spur the market.

The emergence of capsaicin heat therapy patches to temporarily relieve joint or muscle pain caused by minor injuries, such as sprains and strains, is another crucial factor that is estimated to positively affect the growth. Capsaicin is an active ingredient that is commonly found in chili peppers and it is highly effective for the treatment of pain occurring because of osteoarthritis, diabetic neuropathy, and post-operative shingles.

Is the Rising Prevalence of Osteoarthritis Driving the Non-opioid Pain Patches Market?

The increasing prevalence of osteoarthritis across the globe backed by the rising geriatric population, prevalence of joint injuries, obesity, repeated stress on the joint, genetics, metabolic diseases, and bone deformities is set to drive the demand for non-opioid pain relief patches. It is considered to be the most common form of arthritis and occurs very frequently in the knees, hips, and hands.

According to the Osteoarthritis Action Alliance (OAAA), about 54.4 million adults have some form of arthritis in the U.S. and by 2040, this figure is expected to reach 78 million. Amongst these, approximately 32.5 million adults are affected by osteoarthritis. This trend is likely to continue throughout the forthcoming years in various parts of the world, thereby propelling the market.

How are the Increasing Cases of Cancer Propelling the Non-opioid Pain Patches Market?

The growing cases of various types of cancer such as breast, bowel, colorectal, and lungs are expected to drive the market in the upcoming years. The rising awareness by governments of various countries to educate the masses regarding the availability of innovative non-opioid heat patches for the treatment of pain associated with cancer is projected to aid the market.

As per the World Health Organization (WHO), cancer accounted for about 10 million deaths globally in 2020. The same year, there were nearly 6, 85, 000 deaths associated with breast cancer, 8, 30, 000 deaths because of liver cancer, and 1.80 million deaths due to lung cancer. This showcases that the prevalence of cancer is set to surge at a fast pace in the near future, which would drive the market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Insights

What is the U.S. Non-opioid Pain Patches Market Outlook?

“Increasing Geriatric Population to Propel Usage of Non-opioid Heat Patches”

The growing geriatric population in the U.S. is anticipated to boost the non-opioid pain patches market in North America in the assessment period. The geriatric population is prone to chronic and acute pain owing to the higher prevalence of arthritis, musculoskeletal disorders, and cancer among them.

As per U.S. Census Bureau, there were 40.3 million residents belonging to the age group of 65 years and above in 2010 and the number surged by 54.1 million in 2019 in the U.S. The ever-increasing aging population in the country is set to augment the demand for non-opioid heat patches.

How is the U.K. Non-opioid Pain Patches Market Faring?

“Non-opioid Heat Therapy Patches are Being Used by Migraine Patients”

The rising cases of persistent migraines or fibromyalgia in the U.K. is one of the primary factors accelerating the non-opioid pain patches market growth in Europe. Hormonal changes in women, high stress levels, intense physical exertion, changes in sleeping patterns, and increasing consumption of alcohol are some of the leading factors that can often cause migraine.

According to the National Institute for Health and Clinical Excellence, about 190,000 migraine attacks are experienced by people in England every day and approximately 6 million people suffer from this condition in the U.K. The prevalence of migraine has been reported to be 2-10% in men and 5-25% in women. This proves that the cases of migraine are set to surge at a rapid pace in the forthcoming years, which would help in driving the sales of non-opioid heat therapy patches.

Will the India Non-opioid Pain Patches Market Grow at a Steady Pace?

“High Cases of Chronic Pain-related Conditions to Bolster the Sales of Non-opioid Heat Patches”

The increasing cases of chronic pain among people in India is set to propel the South Asia non-opioid pain patches market. The rising investments by the government in the development of a well-established healthcare infrastructure to treat pain-related conditions is also projected to aid the market.

In December 2018, for instance, scientists at the All India Institute of Medical Sciences and Homi Bhabha National Institute conducted a study to understand the impact and magnitude of chronic pain in Southeast Asia. Around 4326 Indian patients were screened and out of these, 836 patients completed a pain questionnaire. The prevalence was higher in females (25.2%) and it increased steeply among people belonging to the age group of 65 years and above. The numbers are estimated to grow in the near future, thereby augmenting the demand for non-opioid heat patches in India. 

Category-wise Insights

Which is the Leading Product Type in the Non-opioid Pain Patches Market?

“Acute and Chronic Pain Patients are Adopting Lidocaine Pain Relief Patches”

Based on product type, the lidocaine patches segment is likely to account for around 68.7% in terms of the global non-opioid pain patches market share in 2022, estimates FMI. These are considered to be the most easily available patches for the treatment of acute and chronic pain.

As per the Centers for Disease Control and Prevention (CDC), nearly 20.4% of adults were suffering from chronic pain in 2019 and the percentage of adults with this type of pain increased as their place of residence became more rural. Thus, the rising cases of chronic pain and the easy availability of lidocaine pain relief patches are anticipated to drive the segment.  

Which is the Preferred Distribution Channel in the Non-opioid Pain Patches Market?

“Senior Citizens are Preferring Online Pharmacies to Order Non-narcotic Pain Patches”

By distribution channel, the online pharmacies segment is set to remain at the forefront in the global non-opioid pain patches market. The emergence of a large number of online pharmacies providing non-narcotic pain patches for treating conditions, such as severe, moderate, and mild chronic and acute pain is a major factor that is projected to bolster the segment.

These pharmacies are also suitable for senior citizens who cannot always get out of their homes to buy medicines. The doorstep delivery facility of these pharmacies would therefore help them to order the required medications from the comfort of their homes.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Competition Landscape

Majority of the key players operating in the global non-opioid pain patches market are focusing on the development of non-addictive topical pain patches for chronic and acute pain. They are also striving to enhance skin adhesion and increase the duration of analgesic action by developing innovative alternative therapeutics. Meanwhile, a few other players are engaging in extensive research and development activities by collaborating with educational institutions to introduce new non-narcotic pain patches.

For instance,

  • In January 2021, a Duke-led team of scientists discovered a novel bio-compatible surgical patch that releases non-opioid painkillers for days to the site of a wound and then dissolves away. The new polymer patch delivers a controlled release of a drug that is capable of blocking the enzyme COX-2 (cyclooxygenase-2,) that propels inflammation and pain.
  • In July 2020, the U.S. Food and Drug Administration (FDA) approved an 8% capsaicin patch for the treatment of neuropathic pain related to diabetic peripheral neuropathy of the feet in adults. The patch is a non-opioid, non-systemic, and topical pain treatment and is considered to be the only treatment available to provide prescription strength capsaicin directly into the patient’s skin.

Scope of Report

Attribute Details
Forecast Period 2014 to 2021
Historical Data Available for 2022 to 2029
Market Analysis Units for Volume and US$ Billion for Value
Key Regions Covered North America; Latin America; Europe; East Asia; South Asia; Oceania; and the Middle East & Africa.
Key Countries Covered United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others.
Key Market Segments Covered Product Type, Distribution Channel, and Region
Key Companies Profiled Sanofi S.A.; Pfizer Inc.; GlaxoSmithKline Plc.; Hisamitsu Pharmaceutical Co., Inc.; Clarion Brands; Endo Pharmaceuticals; TEH SENG Pharmaceutical; Veridian Healthcare; Sorrento Therapeutics (SCILEX Pharmaceuticals) Inc.; Teva Pharmaceutical Industries Ltd.; Teikoku Seiyaku Co. Ltd.
Pricing Available upon Request

Non-opioid Pain Patches Market by Category

Product Type:

  • Lidocaine Patches
  • Diclofenac Patches
  • Methyl Salicylate Patches
  • Capsaicin Patches
  • Ketoprofen Patches
  • Others

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa (MEA)

Frequently Asked Questions

What is the global non-opioid pain patches market size?

The global non-opioid pain patches market is expected to reach a valuation of US$ 3.3 Bn in 2022.

At what rate did the global non-opioid pain patches market grow between 2014 and 2021?

The global non-opioid pain patches market grew at a healthy 2.6% CAGR between 2014 and 2021.

What are the key trends boosting sales of non-opioid pain patches?

The increasing prevalence of cancer and the rising number of online pharmacies are the key trends boosting the sales of non-opioid pain patches.

Who are the leading non-opioid pain patches market players?

Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Hisamitsu Pharmaceutical Co., Inc., Clarion Brands, and Endo Pharmaceuticals are some of the leading players present in the global non-opioid pain patches market.

What is the share of the lidocaine patches segment in the non-opioid pain patches market?

The lidocaine patches segment is anticipated to account for 68.7% of the share in the non-opioid pain patches market in 2022.

What is the share of the diclofenac patches segment in the non-opioid pain patches market?

The diclofenac patches segment is projected to account for 22.6% of the share in the non-opioid pain patches market in the forecast period.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand Side Trends
    1.3. Supply Side Trends
    1.4. Technology Roadmap
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
    2.3. Inclusions and Exclusions
3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Product Innovation / Development Trends
4. Market Background
    4.1. Macro-Economic Factors
        4.1.1. Global GDP Growth Outlook
        4.1.2. Global Healthcare Outlook
    4.2. Forecast Factors - Relevance & Impact
        4.2.1. Research and Developmental Activities
        4.2.2. Technological Advancement
        4.2.3. Adoption of Non-opioid Pain Patches
        4.2.4. Cost of Non-opioid Pain Patches
        4.2.5. Increasing Pain Epidemic  
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities 
5. Market Context
    5.1. Product USPs/ Features
    5.2. Product  Adoption / Usage Analysis
    5.3. Regulatory Scenario
    5.4. Pain Epidemiology 
    5.5. Key Promotional Strategies
6. Global Market Value (US$ Mn) Analysis 2014-2021 and Forecast, 2022-2029
    6.1. Historical Market Value (US$ Mn) Analysis, 2014-2021
    6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029
        6.2.1. Y-o-Y Growth Trend Analysis
        6.2.2. Opportunity Analysis, 2022-2029
7. Global Market - Pricing Analysis
    7.1. Regional Pricing Analysis By Product Type
    7.2. Pricing Break-up
        7.2.1. Manufacturer Level Pricing
        7.2.2. Distributor Level Pricing
    7.3. Global Average Pricing Analysis Benchmark
8. Global Market Analysis 2014-2021 and Forecast 2022-2029, By Product Type
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2014–2021
    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2022-2029
        8.3.1. Lidocaine Patches
        8.3.2. Diclofenac Patches
        8.3.3. Methyl Salicylate Patches
        8.3.4. Capsaicin Patches
        8.3.5. Ketoprofen Patches
        8.3.6. Others 
    8.4. Market Attractiveness Analysis By Product Type
9. Global Market Analysis 2014-2021 and Forecast 2022-2029, By Distribution Channels
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channels, 2014–2021
    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channels, 2022-2029
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies & Drug Stores
        9.3.3. Online Pharmacies 
    9.4. Market Attractiveness Analysis By Distribution Channels
10. Global Market Analysis 2014-2021 and Forecast 2022-2029, by Region
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014–2021
    10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2029
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Europe
        10.3.4. East Asia
        10.3.5. South Asia Pacific
        10.3.6. Middle East and Africa (MEA)
    10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2014-2021 and Forecast 2022-2029
    11.1. Introduction
    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        11.3.1.  By Country
            11.3.1.1. U.S.
            11.3.1.2. Canada
        11.3.2. By Product Type
        11.3.3. By Distribution Channels
        11.3.4. By Region
    11.4. Market Attractiveness Analysis
    11.5. Key Market Participants - Intensity Mapping
    11.6. Drivers and Restraints - Impact Analysis
12. Latin America Market Analysis 2014-2021 and Forecast 2022-2029
    12.1. Introduction
    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        12.3.1. By Country
            12.3.1.1. Brazil
            12.3.1.2. Mexico
            12.3.1.3. Argentina
            12.3.1.4. Rest of Latin America
        12.3.2. By Product Type
        12.3.3. By Distribution Channels
        12.3.4. By Region
    12.4. Market Attractiveness Analysis
    12.5. Key Market Participants - Intensity Mapping
    12.6. Drivers and Restraints - Impact Analysis
13. Europe Market Analysis 2014-2021 and Forecast 2022-2029
    13.1. Introduction
    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        13.3.1. By Country
            13.3.1.1. Germany
            13.3.1.2. Italy
            13.3.1.3. France
            13.3.1.4. U.K.
            13.3.1.5. Spain
            13.3.1.6. Russia
            13.3.1.7. Rest of Europe
        13.3.2. By Product Type
        13.3.3. By Distribution Channels
        13.3.4. By Region
    13.4. Market Attractiveness Analysis
    13.5. Key Market Participants - Intensity Mapping
    13.6. Drivers and Restraints - Impact Analysis
14. South Asia and Oceania Market Analysis 2014-2021 and Forecast 2022-2029
    14.1. Introduction
    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        14.3.1. By Country
            14.3.1.1. India
            14.3.1.2. ASEAN
            14.3.1.3. Australia
            14.3.1.4. New Zealand
        14.3.2. By Product Type
        14.3.3. By Distribution Channels
        14.3.4. By Region
    14.4. Market Attractiveness Analysis
    14.5. Key Market Participants - Intensity Mapping
    14.6. Drivers and Restraints - Impact Analysis
15. East Asia Market Analysis 2014-2021 and Forecast 2022-2029
    15.1. Introduction
    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        15.3.1. By Country
            15.3.1.1. China
            15.3.1.2. Japan
            15.3.1.3. South Korea
        15.3.2. By Product Type
        15.3.3. By Distribution Channels
        15.3.4. By Region
    15.4. Market Attractiveness Analysis
    15.5. Key Market Participants - Intensity Mapping
    15.6. Drivers and Restraints - Impact Analysis
16. Middle East and Africa Market Analysis 2014-2021 and Forecast 2022-2029
    16.1. Introduction
    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2014–2021
    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2029
        16.3.1.  By Country
            16.3.1.1. GCC Countries
            16.3.1.2. Turkey
            16.3.1.3. South Africa
            16.3.1.4. Rest of Middle East and Africa
        16.3.2. By Product Type
        16.3.3. By Distribution Channels
        16.3.4. By Distribution Channels
        16.3.5. By Region
        16.3.6. By Region
    16.4. Market Attractiveness Analysis
    16.5. Key Market Participants - Intensity Mapping
    16.6. Drivers and Restraints - Impact Analysis
17. Key and Emerging Countries Market Analysis 2014-2021 and Forecast 2022-2029
    17.1. Introduction
        17.1.1. Market Value Proportion Analysis, By Key Countries
        17.1.2. Global Vs. Country Growth Comparison
    17.2. U.S. Market Analysis
        17.2.1. By Product Type
        17.2.2. By Distribution Channels
        17.2.3. By Region
    17.3. Canada Market Analysis
        17.3.1. By Product Type
        17.3.2. By Distribution Channels
        17.3.3. By Region
    17.4. Mexico Market Analysis
        17.4.1. By Product Type
        17.4.2. By Distribution Channels
        17.4.3. By Region
    17.5. Brazil Market Analysis
        17.5.1. By Product Type
        17.5.2. By Distribution Channels
        17.5.3. By Region
    17.6. U.K. Market Analysis
        17.6.1. By Product Type
        17.6.2. By Distribution Channels
        17.6.3. By Region
    17.7. Germany Market Analysis
        17.7.1. By Product Type
        17.7.2. By Distribution Channels
        17.7.3. By Region
    17.8. France Market Analysis
        17.8.1. By Product Type
        17.8.2. By Distribution Channels
        17.8.3. By Region
    17.9. Italy Market Analysis
        17.9.1. By Product Type
        17.9.2. By Distribution Channels
        17.9.3. By Region
    17.10. Spain Market Analysis
        17.10.1. By Product Type
        17.10.2. By Distribution Channels
        17.10.3. By Region
    17.11. BENELUX Market Analysis
        17.11.1. By Product Type
        17.11.2. By Distribution Channels
        17.11.3. By Region
    17.12. Russia Market Analysis
        17.12.1. By Product Type
        17.12.2. By Distribution Channels
        17.12.3. By Region
    17.13. China Market Analysis
        17.13.1. By Product Type
        17.13.2. By Distribution Channels
        17.13.3. By Region
    17.14. Japan Market Analysis
        17.14.1. By Product Type
        17.14.2. By Distribution Channels
        17.14.3. By Region
    17.15. South Korea Market Analysis
        17.15.1. By Product Type
        17.15.2. By Distribution Channels
        17.15.3. By Region
    17.16. India Market Analysis
        17.16.1. By Product Type
        17.16.2. By Distribution Channels
        17.16.3. By Region
    17.17. ASEAN Market Analysis
        17.17.1. By Product Type
        17.17.2. By Distribution Channels
        17.17.3. By Region
    17.18. Australia Market Analysis
        17.18.1. By Product Type
        17.18.2. By Distribution Channels
        17.18.3. By Region
    17.19. New Zealand Market Analysis
        17.19.1. By Product Type
        17.19.2. By Raw Material
        17.19.3. By Region
    17.20. GCC Countries Market Analysis
        17.20.1. By Product Type
        17.20.2. By Distribution Channels
        17.20.3. By Region
    17.21. Turkey Market Analysis
        17.21.1. By Product Type
        17.21.2. By Distribution Channels
        17.21.3. By Region
    17.22. South Africa Market Analysis
        17.22.1. By Product Type
        17.22.2. By Distribution Channels
        17.22.3. By Region
18. Market Structure Analysis
    18.1. Market Analysis by Tier of Companies 
    18.2. Market Share Analysis of Top Players
    18.3. Market Presence Analysis
        18.3.1. Regional Footprint by Players
        18.3.2. Product Foot print by Players
        18.3.3. Channel Foot Print by Players
19. Competition Analysis
    19.1. Competition Dashboard
    19.2. Competition Benchmarking
    19.3. Competition Deep Dive (Tentative List)
        19.3.1. Sanofi S.A.
            19.3.1.1. Overview
            19.3.1.2. Product  Portfolio
            19.3.1.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.1.4. Sales Footprint
            19.3.1.5. Strategy Overview
            19.3.1.6. Marketing Strategy
            19.3.1.7. Product Strategy
            19.3.1.8. Channel Strategy
        19.3.2. Pfizer Inc. 
            19.3.2.1. Overview
            19.3.2.2. Product  Portfolio
            19.3.2.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.2.4. Sales Footprint
            19.3.2.5. Strategy Overview
            19.3.2.6. Marketing Strategy
            19.3.2.7. Product Strategy
            19.3.2.8. Channel Strategy
        19.3.3. GlaxoSmithKline Plc. 
            19.3.3.1. Overview
            19.3.3.2. Product  Portfolio
            19.3.3.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.3.4. Sales Footprint
            19.3.3.5. Strategy Overview
            19.3.3.6. Marketing Strategy
            19.3.3.7. Product Strategy
            19.3.3.8. Channel Strategy
        19.3.4. Hisamitsu Pharmaceutical Co., Inc. 
            19.3.4.1. Overview
            19.3.4.2. Product  Portfolio
            19.3.4.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.4.4. Sales Footprint
            19.3.4.5. Strategy Overview
            19.3.4.6. Marketing Strategy
            19.3.4.7. Product Strategy
            19.3.4.8. Channel Strategy
        19.3.5. Clarion Brands
            19.3.5.1. Overview
            19.3.5.2. Product  Portfolio
            19.3.5.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.5.4. Sales Footprint
            19.3.5.5. Strategy Overview
            19.3.5.6. Marketing Strategy
            19.3.5.7. Product Strategy
            19.3.5.8. Channel Strategy
        19.3.6. Endo Pharmaceuticals 
            19.3.6.1. Overview
            19.3.6.2. Product  Portfolio
            19.3.6.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.6.4. Sales Footprint
            19.3.6.5. Strategy Overview
            19.3.6.6. Marketing Strategy
            19.3.6.7. Product Strategy
            19.3.6.8. Channel Strategy
        19.3.7. TEH SENG Pharmaceutical 
            19.3.7.1. Overview
            19.3.7.2. Product  Portfolio
            19.3.7.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.7.4. Sales Footprint
            19.3.7.5. Strategy Overview
            19.3.7.6. Marketing Strategy
            19.3.7.7. Product Strategy
            19.3.7.8. Channel Strategy
        19.3.8. Veridian Healthcare 
            19.3.8.1. Overview
            19.3.8.2. Product  Portfolio
            19.3.8.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.8.4. Sales Footprint
            19.3.8.5. Strategy Overview
            19.3.8.6. Marketing Strategy
            19.3.8.7. Product Strategy
            19.3.8.8. Channel Strategy
        19.3.9. Sorrento Therapeutics (SCILEX Pharmaceuticals Inc.) 
            19.3.9.1. Overview
            19.3.9.2. Product  Portfolio
            19.3.9.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.9.4. Sales Footprint
            19.3.9.5. Strategy Overview
            19.3.9.6. Marketing Strategy
            19.3.9.7. Product Strategy
            19.3.9.8. Channel Strategy
        19.3.10. Teva Pharmaceutical Industries Ltd.
            19.3.10.1. Overview
            19.3.10.2. Product  Portfolio
            19.3.10.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.10.4. Sales Footprint
            19.3.10.5. Strategy Overview
            19.3.10.6. Marketing Strategy
            19.3.10.7. Product Strategy
            19.3.10.8. Channel Strategy
        19.3.11. Teikoku Seiyaku Co. Ltd. 
            19.3.11.1. Overview
            19.3.11.2. Product  Portfolio
            19.3.11.3. Profitability by Market Segments (Product/Channel/Region)
            19.3.11.4. Sales Footprint
            19.3.11.5. Strategy Overview
            19.3.11.6. Marketing Strategy
            19.3.11.7. Product Strategy
            19.3.11.8. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology
Recommendations

Healthcare

Vascular Patches Market

August 2024

REP-GB-12868

310 pages

Healthcare

Analgesics Market

April 2024

REP-GB-1306

312 pages

Healthcare

Opioid Analgesics Market

August 2023

REP-GB-14043

306 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Non-opioid Pain Patches Market

Schedule a Call